NO2017044I1 - iksekizumab - Google Patents

iksekizumab

Info

Publication number: NO2017044I1
Authority: NO; Norway
Prior art keywords: iksekizumab
Prior art date: 2005-12-13

Application number

NO2017044C

Other languages

English (en)

Other versions

NO2017044I2 (no

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-13

Filing date

2017-08-18

Publication date

2017-08-18

2017-08-18 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2017-08-18 Publication of NO2017044I1 publication Critical patent/NO2017044I1/no

2017-08-18 Publication of NO2017044I2 publication Critical patent/NO2017044I2/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Neurosurgery (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

NO2017044C 2005-12-13 2017-08-18 iksekizumab NO2017044I2 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US74995305P	2005-12-13	2005-12-13
US80194806P	2006-05-19	2006-05-19
PCT/US2006/061586 WO2007070750A1 (en)	2005-12-13	2006-12-05	Anti-il-17 antibodies

Publications (2)

Publication Number	Publication Date
NO2017044I1 true NO2017044I1 (no)	2017-08-18
NO2017044I2 NO2017044I2 (no)	2017-08-18

Family

ID=38008638

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20082905A NO340827B1 (no)	2005-12-13	2008-06-26	Anti-IL-17-antistoffer
NO2017044C NO2017044I2 (no)	2005-12-13	2017-08-18	iksekizumab

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NO20082905A NO340827B1 (no)	2005-12-13	2008-06-26	Anti-IL-17-antistoffer

Country Status (23)

Country	Link
US (2)	US7838638B2 (no)
EP (4)	EP2481753B1 (no)
JP (1)	JP5063612B2 (no)
KR (1)	KR101158959B1 (no)
CN (1)	CN101326195B9 (no)
AU (1)	AU2006325860B2 (no)
BR (1)	BRPI0619792B1 (no)
CA (1)	CA2631938C (no)
CY (3)	CY1113097T1 (no)
DK (2)	DK1963368T6 (no)
EA (1)	EA014298B1 (no)
ES (2)	ES2672221T3 (no)
HR (2)	HRP20120606T4 (no)
HU (2)	HUE039353T2 (no)
IL (1)	IL191217A (no)
LT (2)	LT2481753T (no)
LU (1)	LU93189I2 (no)
NO (2)	NO340827B1 (no)
PL (2)	PL1963368T6 (no)
PT (2)	PT1963368E (no)
RS (2)	RS52509B2 (no)
SI (2)	SI2481753T1 (no)
WO (1)	WO2007070750A1 (no)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2305879T3 (es)	2003-11-21	2008-11-01	Ucb Pharma, S.A.	Metodo para el tratamiento de la esclerosis multiple mediante inhibicion de la actividad il-17.
WO2007070750A1 (en) *	2005-12-13	2007-06-21	Eli Lilly And Company	Anti-il-17 antibodies
EP2377887A1 (en)	2006-03-10	2011-10-19	Zymogenetics Inc	Antibodies that bind both IL-17A and IL-17F and methods of using the same
US7790163B2 (en)	2006-03-10	2010-09-07	Zymogenetics, Inc.	Antibodies that bind both IL-17A and IL-17F and methods of using the same
US7910703B2 (en)	2006-03-10	2011-03-22	Zymogenetics, Inc.	Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
TW200815469A (en)	2006-06-23	2008-04-01	Astrazeneca Ab	Compounds
GB0612928D0 (en)	2006-06-29	2006-08-09	Ucb Sa	Biological products
MX2009001620A (es)	2006-08-11	2009-02-23	Schering Corp	Anticuerpos para il-17a.
GB0620729D0 (en)	2006-10-18	2006-11-29	Ucb Sa	Biological products
RU2009137582A (ru)	2007-03-12	2011-04-20	Эсбатек Аг (Ch)	Инженерия и оптимизация одноцепочечных антител на основе последовательности
US9908945B2 (en)	2007-06-25	2018-03-06	Esbatech, An Alcon Biomedical Research Unit Llc	Sequence based engineering and optimization of single chain antibodies
CN101849001B (zh) *	2007-06-25	2014-07-16	艾斯巴技术-诺华有限责任公司	修饰抗体的方法和具有改善的功能性质的修饰抗体
US20110300154A1 (en) *	2007-08-21	2011-12-08	Children's Medical Center Corporation	Treatment of airway hyperreactivity
WO2009082624A2 (en) *	2007-12-10	2009-07-02	Zymogenetics, Inc.	Antagonists of il-17a, il-17f, and il-23 and methods of using the same
GB0807413D0 (en)	2008-04-23	2008-05-28	Ucb Pharma Sa	Biological products
KR20110025649A (ko)	2008-05-05	2011-03-10	노비뮨 에스 에이	항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
NZ591484A (en) *	2008-09-29	2012-09-28	Roche Glycart Ag	Antibodies against human il 17 and uses thereof
MX2011004998A (es) *	2008-11-12	2011-05-25	Schering Corp	Intron de beta-globina-inmunoglobina gamma para la expresion mejorada del anti-factor de crecimiento similar a la insulina 1r.
US20110223169A1 (en) *	2008-11-26	2011-09-15	Stern Michael E	Il-17 antibody inhibitor for treating dry eye
WO2010062857A1 (en)	2008-11-26	2010-06-03	Allergan, Inc.	Klk-13 antibody inhibitor for treating dry eye
RU2015132478A (ru) *	2009-03-05	2015-12-10	Эббви Инк.	Связывающие il-17 белки
JP6053517B2 (ja)	2009-05-05	2016-12-27	ノヴィミュンヌエスア	抗ｉｌ−１７ｆ抗体およびそれらの使用法
KR101836217B1 (ko)	2009-10-30	2018-03-08	얀센 바이오테크 인코포레이티드	Ｉｌ-１７ａ 길항제
JO3417B1 (ar)	2010-01-08	2019-10-20	Regeneron Pharma	الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
ES2993140T3 (en)	2010-04-02	2024-12-23	Amunix Pharmaceuticals Inc	Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
US20110293629A1 (en)	2010-05-14	2011-12-01	Bastid Jeremy	Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
ES2633145T3 (es)	2010-08-05	2017-09-19	Anaptysbio, Inc.	Anticuerpos dirigidos contra IL-17
TW201302793A (zh)	2010-09-03	2013-01-16	Glaxo Group Ltd	新穎之抗原結合蛋白
RU2591083C2 (ru)	2010-10-08	2016-07-10	Новартис Аг	Способы лечения псориаза с использованием антагонистов il-17
WO2021239743A1 (en)	2020-05-27	2021-12-02	Sanofi	Il-17a modulators
US10208349B2 (en)	2011-01-07	2019-02-19	Ucb Biopharma Sprl	Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
GB201100282D0 (en)	2011-01-07	2011-02-23	Ucb Pharma Sa	Biological methods
MA34907B1 (fr)	2011-01-14	2014-02-01	Ucb Pharma Sa	Molécules d'anticorps se liant à il-17a et il-17f
TWI589299B (zh)	2011-10-11	2017-07-01	再生元醫藥公司	用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en)	2011-10-11	2018-04-17	Sanofi Biotechnology	Methods for the treatment of rheumatoid arthritis
CA2856252A1 (en)	2011-11-21	2013-05-30	Novartis Ag	Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non-response alleles
EP2809660B1 (en)	2012-02-02	2016-01-20	Ensemble Therapeutics Corporation	Macrocyclic compounds for modulating il-17
MX362191B (es)	2012-03-07	2019-01-08	Lilly Co Eli	Formulacion de anticuerpo il-17.
KR20150010709A (ko)	2012-04-20	2015-01-28	노파르티스 아게	Il-17 길항제를 사용하는 강직성 척추염의 치료 방법
AR090626A1 (es) *	2012-04-20	2014-11-26	Lilly Co Eli	Anticuerpos anti-baff-anti-il-17 biespecificos
CN104884473B (zh)	2012-05-22	2019-12-03	百时美施贵宝公司	Il-17a/f il-23双特异性抗体及其应用
US9676847B2 (en)	2012-06-25	2017-06-13	Orega Biotech	IL-17 antagonist antibodies
WO2014066726A2 (en)	2012-10-26	2014-05-01	Ensemble Therapeutics Corporation	Compounds for modulating il-17
SG11201504035PA (en)	2012-11-29	2015-06-29	Bayer Healthcare Llc	Humanized monoclonal antibodies against activated protein c and uses thereof
CA2897682C (en) *	2013-02-08	2023-03-14	Novartis Ag	Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
TW201444867A (zh)	2013-03-08	2014-12-01	Lilly Co Eli	抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
WO2014155278A2 (en)	2013-03-26	2014-10-02	Novartis Ag	Methods of treating autoimmune diseases using il-17 antagonists
US9700485B2 (en)	2013-04-24	2017-07-11	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US20150004133A1 (en) *	2013-06-07	2015-01-01	The Regents Of The University Of California	Compositions And Methods For Treating Steatohepatitis, Liver Fibrosis, and Hepatocellular Carcinoma (HCC)
US9603882B2 (en)	2013-08-13	2017-03-28	Industrial Technology Research Institute	Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
EP4223312A1 (en)	2013-08-15	2023-08-09	Novartis AG	Methods of treating plaque psoriasis using il-17 antagonists
PT3072905T (pt) *	2013-11-18	2020-09-17	Shanghai hengrui pharmaceutical co ltd	Agente de ligação a il-17a e suas utilizações
US11421025B2 (en)	2013-12-27	2022-08-23	Osaka University	Treatment of IL-17A diseases
US10519251B2 (en) *	2013-12-30	2019-12-31	Epimab Biotherapeutics, Inc.	Fabs-in-tandem immunoglobulin and uses thereof
JP2017507939A (ja)	2014-02-21	2017-03-23	ジェネンテック，インコーポレイテッド	抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
RU2577228C2 (ru) *	2014-03-14	2016-03-10	Закрытое Акционерное Общество "Биокад"	Анти-il-17-антитела, способ их получения и способ применения
TWI713453B (zh)	2014-06-23	2020-12-21	美商健生生物科技公司	干擾素α及ω抗體拮抗劑
JP2017528465A (ja)	2014-09-10	2017-09-28	ノバルティスアーゲー	乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ−１７アンタゴニストの使用
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US9988452B2 (en)	2014-10-14	2018-06-05	Novartis Ag	Antibody molecules to PD-L1 and uses thereof
AR103173A1 (es)	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
DK3245224T3 (da)	2015-01-12	2020-09-21	Affibody Ab	Il-17a-bindende polypeptider
HK1245882A1 (zh)	2015-01-28	2018-08-31	F. Hoffmann-La Roche Ag	多發性硬化的基因表達標志和治療
CN106336459B (zh) *	2015-07-13	2020-12-08	三生国健药业（上海）股份有限公司	抗人白细胞介素-17a单克隆抗体、其制备方法和应用
EA201792527A1 (ru)	2015-07-16	2018-06-29	Эли Лилли Энд Компани	Лечение зуда
US20180207273A1 (en)	2015-07-29	2018-07-26	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
EP4378957A3 (en)	2015-07-29	2024-08-07	Novartis AG	Combination therapies comprising antibody molecules to pd-1
SI3317301T1 (sl)	2015-07-29	2021-10-29	Novartis Ag	Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
WO2017087391A1 (en)	2015-11-17	2017-05-26	Bayer Healthcare, Llc	Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof
AU2016369537B2 (en)	2015-12-17	2024-03-14	Novartis Ag	Antibody molecules to PD-1 and uses thereof
TWI738713B (zh)	2016-02-06	2021-09-11	開曼群島商岸邁生物科技有限公司	Fabs串聯免疫球蛋白及其用途
CN107488227A (zh) *	2016-06-12	2017-12-19	三生国健药业（上海）股份有限公司	抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
WO2017221174A1 (en)	2016-06-22	2017-12-28	Novartis Ag	Methods of treating vitiligo using interleukin-17 (il-17) antibodies
ES2992409T3 (es)	2016-07-19	2024-12-12	Novartis Ag	Métodos de tratamiento de la psoriasis en placas de nueva aparición usando antagonistas de IL-17
BR112019004990A2 (pt) *	2016-09-14	2019-06-04	Beijing hanmi pharm co ltd	anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo
WO2018096467A1 (en)	2016-11-28	2018-05-31	Novartis Ag	Methods of treating acne using interleukin-17 (il-17) antagonists
WO2018148585A1 (en)	2017-02-10	2018-08-16	Genentech, Inc.	Anti-tryptase antibodies, compositions thereof, and uses thereof
WO2018158741A1 (en)	2017-03-03	2018-09-07	Novartis Ag	Psoriasis disease modification following long-term treatment with an il-17 antagonist
EP3592771A4 (en) *	2017-03-10	2020-09-09	Suzhou Kanova Biopharmaceutical Co., Ltd.	MONOCLONAL ANTIBODIES AGAINST BOTH IL-17A AND IL-17F AND USE THEREOF
US10941178B2 (en) *	2017-03-17	2021-03-09	Gilead Sciences, Inc.	Method of purifying an antibody
TW201842933A (zh)	2017-05-05	2018-12-16	瑞士商諾華公司	使用il-17拮抗劑選擇性治療氣喘的方法
US11299540B2 (en)	2017-06-18	2022-04-12	Kindred Biosciences, Inc.	IL17A antibodies and antagonists for veterinary use
WO2019027828A1 (en)	2017-08-04	2019-02-07	Eli Lilly And Company	DOSAGE SCHEME OF ANTI-IL-17 ANTIBODIES
EP3672988A1 (en)	2017-08-23	2020-07-01	Eli Lilly and Company	Treatment of genital psoriasis
JP2021501752A (ja)	2017-11-02	2021-01-21	ノバルティスアーゲー	インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用して腱障害を治療する方法
US20200347130A1 (en) *	2017-11-10	2020-11-05	Jiangsu Hengrui Medicine Co., Ltd.	CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
KR102048475B1 (ko) *	2017-11-10	2019-11-26	주식회사 와이바이오로직스	IL-17A (Interleukin-17A)에 특이적으로 결합하는 항체 및 이의 용도
US20200277369A1 (en)	2017-11-20	2020-09-03	Novartis Ag	Method of treating hidradentitis suppurativa with il-17 antagonists
KR20200096253A (ko)	2017-11-30	2020-08-11	노파르티스 아게	Bcma-표적화 키메라 항원 수용체, 및 이의 용도
US11619832B2 (en)	2018-03-08	2023-04-04	Coopervision International Limited	Identification of contact lens wearers predisposed to contact lens discomfort
AU2019263850A1 (en)	2018-05-03	2020-11-19	Shanghai Epimab Biotherapeutics Co., Ltd.	High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom
AU2018423921B2 (en)	2018-05-17	2021-09-30	Jiangsu Qyuns Therapeutics Co., Ltd.	Anti-human interleukin 17A monoclonal antibody and application thereof
KR20210016390A (ko)	2018-06-01	2021-02-15	노파르티스 아게	Bcma에 대한 결합 분자 및 이의 용도
GB201810327D0 (en)	2018-06-22	2018-08-08	Bicycletx Ltd	Peptide ligands for binding to IL-17
WO2020047029A1 (en)	2018-08-29	2020-03-05	Regeneron Pharmaceuticals, Inc.	Methods and compositions for treating subjects having rheumatoid arthritis
EP3856772A1 (en)	2018-09-25	2021-08-04	Institut National de la Santé et de la Recherche Médicale (INSERM)	Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
CN111018974B (zh) *	2018-10-10	2022-04-01	东莞市朋志生物科技有限公司	一种抗人心肌肌钙蛋白i的重组抗体
GB201820316D0 (en)	2018-12-13	2019-01-30	Bicyclerd Ltd	Bicyclic peptide ligands specific for IL-17
CN109369806B (zh) *	2019-01-14	2019-04-19	迈威(上海)生物科技有限公司	苏金单抗制品中半胱氨酸化变异体的去除方法
EP3689907A1 (en)	2019-01-31	2020-08-05	Numab Therapeutics AG	Antibodies targeting il-17a and methods of use thereof
CN114206442A (zh)	2019-01-31	2022-03-18	赛诺菲生物技术公司	用于治疗幼年特发性关节炎的抗il-6受体抗体
CA3127935A1 (en)	2019-01-31	2020-08-06	Numab Therapeutics AG	Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
US11634485B2 (en) *	2019-02-18	2023-04-25	Eli Lilly And Company	Therapeutic antibody formulation
KR102400401B1 (ko) *	2019-05-22	2022-05-24	(주)셀인바이오	항염증 펩타이드 및 항염증 조성물
TW202110892A (zh)	2019-06-04	2021-03-16	法商賽諾菲生物技術公司	治療具有類風濕性關節炎的個體中疼痛之組成物及方法
MX2022001068A (es)	2019-07-26	2022-02-14	Sinocelltech Ltd	Anticuerpo anti-il17a humanizado y uso del mismo.
US20220267432A1 (en)	2019-07-30	2022-08-25	Jiangsu Hengrui Medicine Co., Ltd.	Method for treating autoimmune disease by il-17 antagonist
AU2020347952A1 (en)	2019-09-20	2022-04-07	Novartis Ag	Methods of treating autoimmune diseases using interleukin-17 (IL-17) antagonists
AU2020368369A1 (en)	2019-10-15	2022-05-12	Eli Lilly And Company	Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CN114728060A (zh)	2019-11-19	2022-07-08	诺华股份有限公司	使用白介素-17（il-17）拮抗剂治疗狼疮性肾炎的方法
AU2020396455A1 (en)	2019-12-06	2022-06-02	Novartis Ag	Methods of treating lichen planus using Interleukin-17 (IL-17) antagonists
GB201918557D0 (en)	2019-12-16	2020-01-29	Bicycle Tx Ltd	Bicyclic peptide ligands specific for IL-17
GB201918558D0 (en)	2019-12-16	2020-01-29	Bicycle Tx Ltd	Bicyclic peptide ligands specific for IL-17
WO2021123767A1 (en)	2019-12-16	2021-06-24	Bicycletx Limited	Bicyclic peptide ligands specific for il-17
GB201918559D0 (en)	2019-12-16	2020-01-29	Bicycle Tx Ltd	Bicyclic peptide ligands specific for IL-17
GB201919062D0 (en) *	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Antibody
EP4157828A1 (en)	2020-05-27	2023-04-05	Sanofi	Il-17a modulators
EP4168117A1 (en)	2020-06-23	2023-04-26	Novartis AG	Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists
EP4240491A1 (en)	2020-11-06	2023-09-13	Novartis AG	Cd19 binding molecules and uses thereof
CN115746132B (zh) *	2021-09-03	2023-09-08	三优生物医药(上海)有限公司	抗il-17a抗体及其用途
IT202100023816A1 (it) *	2021-09-16	2023-03-16	Takis S R L	Anticorpo contro SARS-CoV-2 e suoi usi in campo medico.
CN113896793B (zh) *	2021-09-30	2023-05-26	港科鹏禾生物(苏州)有限公司	一种抗人il-17rc的单克隆抗体及其应用
EP4525984A1 (en)	2022-05-16	2025-03-26	Novartis AG	Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists
AU2023270497A1 (en)	2022-05-18	2024-12-05	Novartis Ag	Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists
WO2024121427A1 (en)	2022-12-09	2024-06-13	Sanofi	Therapeutic compounds
WO2025083549A1 (en)	2023-10-16	2025-04-24	Sun Pharma Advanced Research Company Limited	Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders
WO2025104230A1 (en)	2023-11-17	2025-05-22	Sanofi	Benzoxazoles as modulators of il-17a

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5225A (en)		1847-08-07		Latch
US539A (en)		1837-12-26		Standard measurer for taking measure for coats
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es)	1990-08-29	1997-12-16	Genpharm Int	Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
CA2090473A1 (en)	1990-08-29	1992-03-01	Robert M. Kay	Homologous recombinatin in mammalian cells
US6284471B1 (en)	1991-03-18	2001-09-04	New York University Medical Center	Anti-TNFa antibodies and assays employing anti-TNFa antibodies
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
AU2515992A (en)	1991-08-20	1993-03-16	Genpharm International, Inc.	Gene targeting in animal cells using isogenic dna constructs
JP3571337B2 (ja)	1992-02-11	2004-09-29	セルジェネシス，インコーポレーテッド	遺伝子標的現象による同型遺伝子接合
US6274711B1 (en)	1993-06-14	2001-08-14	Inserm, Institut National De La Sante Et De La Recherche Medicale	Purified mammalian CTLA-8 antigens and related reagents
US6562333B1 (en)	1993-06-14	2003-05-13	Schering Corporation	Purified mammalian CTLA-8 antigens and related reagents
US5625825A (en)	1993-10-21	1997-04-29	Lsi Logic Corporation	Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5698762A (en)	1994-12-09	1997-12-16	Dauerman; Leonard	Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
EP0773288A3 (en)	1995-08-29	1997-07-09	Kirin Brewery	Chimera animal and its method of manufacture
GB0312481D0 (en)	2003-05-30	2003-07-09	Celltech R&D Ltd	Antibodies
US20050033029A1 (en)	2003-06-30	2005-02-10	Jin Lu	Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
ES2305879T3 (es)	2003-11-21	2008-11-01	Ucb Pharma, S.A.	Metodo para el tratamiento de la esclerosis multiple mediante inhibicion de la actividad il-17.
GB0417487D0 (en) *	2004-08-05	2004-09-08	Novartis Ag	Organic compound
GB0425569D0 (en) *	2004-11-19	2004-12-22	Celltech R&D Ltd	Biological products
WO2007070750A1 (en)	2005-12-13	2007-06-21	Eli Lilly And Company	Anti-il-17 antibodies

2006
- 2006-12-05 WO PCT/US2006/061586 patent/WO2007070750A1/en active Application Filing
- 2006-12-05 LT LTEP11192240.7T patent/LT2481753T/lt unknown
- 2006-12-05 DK DK06846464.3T patent/DK1963368T6/da active
- 2006-12-05 US US12/095,398 patent/US7838638B2/en active Active
- 2006-12-05 CN CN200680046605.8A patent/CN101326195B9/zh active Active
- 2006-12-05 EP EP11192240.7A patent/EP2481753B1/en active Active
- 2006-12-05 EP EP20190492.7A patent/EP3808769A1/en active Pending
- 2006-12-05 JP JP2008545908A patent/JP5063612B2/ja active Active
- 2006-12-05 PL PL06846464T patent/PL1963368T6/pl unknown
- 2006-12-05 PT PT06846464T patent/PT1963368E/pt unknown
- 2006-12-05 HR HRP20120606TT patent/HRP20120606T4/hr unknown
- 2006-12-05 HU HUE11192240A patent/HUE039353T2/hu unknown
- 2006-12-05 SI SI200632258T patent/SI2481753T1/en unknown
- 2006-12-05 ES ES11192240.7T patent/ES2672221T3/es active Active
- 2006-12-05 CA CA2631938A patent/CA2631938C/en active Active
- 2006-12-05 AU AU2006325860A patent/AU2006325860B2/en active Active
- 2006-12-05 BR BRPI0619792-2A patent/BRPI0619792B1/pt active IP Right Grant
- 2006-12-05 EA EA200870050A patent/EA014298B1/ru active Protection Beyond IP Right Term
- 2006-12-05 PL PL11192240T patent/PL2481753T3/pl unknown
- 2006-12-05 EP EP18160779.7A patent/EP3366702B1/en active Active
- 2006-12-05 ES ES06846464T patent/ES2389780T7/es active Active
- 2006-12-05 DK DK11192240.7T patent/DK2481753T3/en active
- 2006-12-05 RS RS20120418A patent/RS52509B2/sr unknown
- 2006-12-05 EP EP06846464.3A patent/EP1963368B3/en active Active
- 2006-12-05 KR KR1020087014147A patent/KR101158959B1/ko active Active
- 2006-12-05 RS RS20180601A patent/RS57255B1/sr unknown
- 2006-12-05 PT PT111922407T patent/PT2481753T/pt unknown
- 2006-12-05 SI SI200631427T patent/SI1963368T1/sl unknown
2008
- 2008-05-01 IL IL191217A patent/IL191217A/en active Protection Beyond IP Right Term
- 2008-06-26 NO NO20082905A patent/NO340827B1/no active Protection Beyond IP Right Term
2010
- 2010-10-21 US US12/908,892 patent/US8110191B2/en active Active
2012
- 2012-09-07 CY CY20121100807T patent/CY1113097T1/el unknown
2016
- 2016-08-24 CY CY2016030C patent/CY2016030I1/el unknown
- 2016-08-25 LT LTPA2016026C patent/LTC1963368I2/lt unknown
- 2016-08-31 LU LU93189C patent/LU93189I2/fr unknown
- 2016-09-07 HU HUS1600037C patent/HUS1600037I1/hu unknown
2017
- 2017-08-18 NO NO2017044C patent/NO2017044I2/no unknown
2018
- 2018-06-15 HR HRP20180941TT patent/HRP20180941T1/hr unknown
- 2018-06-27 CY CY20181100670T patent/CY1120365T1/el unknown

Also Published As

Publication number	Publication date
EP2481753A1 (en)	2012-08-01
EP1963368B1 (en)	2012-07-18
CN101326195A (zh)	2008-12-17
ES2672221T3 (es)	2018-06-13
EP3366702A1 (en)	2018-08-29
LTC1963368I2 (lt)	2018-01-10
KR20080068122A (ko)	2008-07-22
US8110191B2 (en)	2012-02-07
PL1963368T6 (pl)	2021-02-08
CY1120365T1 (el)	2019-07-10
RS57255B1 (sr)	2018-08-31
WO2007070750A1 (en)	2007-06-21
PL1963368T3 (pl)	2012-11-30
RS52509B (en)	2013-04-30
EP2481753B1 (en)	2018-04-18
BRPI0619792A2 (pt)	2011-10-18
KR101158959B1 (ko)	2012-07-09
HRP20120606T1 (en)	2012-10-31
ES2389780T3 (es)	2012-10-31
US20080269467A1 (en)	2008-10-30
PT2481753T (pt)	2018-07-13
CA2631938C (en)	2014-05-20
EP3366702B1 (en)	2023-08-09
RS52509B2 (sr)	2020-09-30
DK1963368T3 (da)	2012-08-06
DK1963368T6 (da)	2020-06-29
HK1120275A1 (en)	2009-03-27
AU2006325860B2 (en)	2011-09-22
PL2481753T3 (pl)	2018-09-28
JP5063612B2 (ja)	2012-10-31
HRP20120606T4 (hr)	2020-08-07
EP3808769A1 (en)	2021-04-21
EA200870050A1 (ru)	2009-12-30
LU93189I2 (fr)	2016-10-31
CY1113097T1 (el)	2016-04-13
NO20082905L (no)	2008-09-03
AU2006325860A1 (en)	2007-06-21
PT1963368E (pt)	2012-09-14
ES2389780T7 (es)	2021-01-14
HRP20180941T1 (hr)	2018-08-10
JP2009519348A (ja)	2009-05-14
CA2631938A1 (en)	2007-06-21
DK2481753T3 (en)	2018-06-18
CY2016030I2 (el)	2016-12-14
EP1963368B3 (en)	2020-06-10
HUE039353T2 (hu)	2018-12-28
BRPI0619792B1 (pt)	2021-09-28
US7838638B2 (en)	2010-11-23
LTPA2016026I1 (lt)	2016-09-26
SI2481753T1 (en)	2018-06-29
CN101326195B9 (zh)	2022-11-11
LT2481753T (lt)	2018-05-25
US20110027290A1 (en)	2011-02-03
SI1963368T1 (sl)	2012-11-30
CN101326195B (zh)	2012-01-11
CY2016030I1 (el)	2016-12-14
NO2017044I2 (no)	2017-08-18
IL191217A (en)	2015-10-29
NO340827B1 (no)	2017-06-26
EP1963368A1 (en)	2008-09-03
HUS1600037I1 (hu)	2016-10-28
EA014298B1 (ru)	2010-10-29

Publication	Publication Date	Title
NO2017044I1 (no)	2017-08-18	iksekizumab
ATE408603T1 (de)	2008-10-15	Pyrazolylcarboxanilide
DE602005020856D1 (de)	2010-06-02	Unterhose
DE602006000103D1 (de)	2007-10-25	Ansaugtraktanordnung
DE602006000345D1 (de)	2008-01-31	Scheibenbremsaktuator
DE502006003394D1 (de)	2009-05-20	Lehnenklappung
DE602006000257D1 (de)	2008-01-03	Elektronenstrahlsterilisator
DE502006008475D1 (de)	2011-01-20	Wasserpumpenflügelrad
DE502006005667D1 (de)	2010-01-28	Gelenklager
DE602005011440D1 (de)	2009-01-15	Höhenmessuhr
ATE549324T1 (de)	2012-03-15	Tetrahydrobenzoxazine
DE502006006857D1 (de)	2010-06-10	Wingungserregern
DE502006005768D1 (de)	2010-02-11	Hydrolysestabilisatorformulierungen
DE602005006405D1 (de)	2008-06-12	Maisabstreifer
DE112006002964A5 (de)	2008-09-11	Zweirichtungsreflektanzverteilungsmessgerät
DE602006000139D1 (de)	2007-11-15	Biderzeugungsvorrichtung
FI20055715A0 (fi)	2005-12-30	Turboekvalisointimenettely
DE502006004302D1 (de)	2009-09-03	Verschlusskappe
DE502006001397D1 (de)	2008-10-02	Lagerbuchse
DE602005009179D1 (de)	2008-10-02	Telekommunikatiosverbinder
DE502006001004D1 (de)	2008-08-14	Hydrolager
ATE485368T1 (de)	2010-11-15	Hiv - impfung
DE502006003147D1 (de)	2009-04-30	Verbundgußplatte
DE602005023501D1 (de)	2010-10-21	Radhausbau
DE602005021060D1 (de)	2010-06-17	Notrufleitweglenkung